Vulva Cancer malady

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Vulva Cancer

Aliases & Descriptions for Vulva Cancer:

Name: Vulva Cancer 12 14
Vulva Carcinoma 12 52 14
Carcinoma of Vulva 12 69
Vulvar Neoplasms 42 69
Vulvar Cancer 50 41
Malignant Neoplasm of Vulva, Unspecified 12
Malignant Neoplasm of Vulva Unspecified 12
Malignant Neoplasm of Vulva, Nos 12
Malignant Neoplasm of Vulva 69
Malignant Tumor of Vulva 12
Malignant Vulvar Tumor 12
Neoplasm of Vulva 12
Vulvar Carcinoma 12
Vulval Neoplasm 12
Vulvar Neoplasm 12
Vulval Cancer 12
Vulvar Tumor 12
Ca Vulva 12


Summaries for Vulva Cancer

MedlinePlus : 41 vulvar cancer is a rare type of cancer. it forms in a woman's external genitals, called the vulva. the cancer usually grows slowly over several years. first, precancerous cells grow on vulvar skin. this is called vulvar intraepithelial neoplasia (vin), or dysplasia. not all vin cases turn into cancer, but it is best to treat it early. often, vulvar cancer doesn't cause symptoms at first. however, see your doctor for testing if you notice a lump in the vulva vulvar itching or tenderness bleeding that is not your period changes in the vulvar skin, such as color changes or growths that look like a wart or ulcer you are at greater risk if you've had a human papillomavirus (hpv) infection or have a history of genital warts. your health care provider diagnoses vulvar cancer with a physical exam and a biopsy. treatment varies, depending on your overall health and how advanced the cancer is. it might include surgery, radiation therapy, chemotherapy, or biologic therapy. biologic therapy boosts your body's own ability to fight cancer. nih: national cancer institute

MalaCards based summary : Vulva Cancer, also known as vulva carcinoma, is related to vulva squamous cell carcinoma and clitoris cancer, and has symptoms including pruritus vulvae and pelvic pain. An important gene associated with Vulva Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Pancreatic cancer and L1CAM interactions. The drugs Gardasil and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and cervix.

NIH Rare Diseases : 50 vulvar cancer is the abnormal growth of cells of the vulva, which is part of the female reproductive system and includes the vaginal lips, clitoris, and part of the vagina.  symptoms of vulvar cancer may consist of a lump (mass), itching, or unusual bleeding.  though the exact cause of this cancer is unknown, older women and those who have human papillomavirus have a higher chance of developing vulvar cancer.  treatment may include laser therapy, surgery, chemotherapy, or radiation therapy. last updated: 7/27/2012

Disease Ontology : 12 A vulva cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia : 71 Vulvar cancer is a malignant, invasive growth in the vulva, or the outer portion of the female genitals.... more...

Related Diseases for Vulva Cancer

Diseases related to Vulva Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 vulva squamous cell carcinoma 30.9 CDKN2A LINC01191 PIP UPK3A
2 clitoris cancer 30.3 KRT13 UPK3A
3 bartholin's gland benign neoplasm 10.9
4 vulva adenocarcinoma 10.9
5 vaginal disease 10.9
6 vulvar disease 10.9
7 wolffian adnexal neoplasm 10.3 EGFR TP53
8 clear cell adenofibroma 10.3 CDKN2A TP53
9 immunodeficiency due to a classical component pathway complement deficiency 10.3 CDKN2A EGFR
10 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
11 pericardium leiomyoma 10.3 CDKN2A TP53
12 spondylarthropathy 10.3 CDKN2A TP53
13 urethral villous adenoma 10.3 CDKN2A EGFR
14 paternal uniparental disomy of chromosome 1 10.3 EGFR TP53
15 lacrimal gland squamous cell carcinoma 10.3 CDKN2A TP53
16 brainstem intraparenchymal clear cell meningioma 10.3 EGFR TP53
17 endometrial squamous cell carcinoma 10.3 CDKN2A TP53
18 ampulla of vater neoplasm 10.3 CDKN2A TP53
19 postpoliomyelitis syndrome 10.3 CDKN2A TP53
20 paraphimosis 10.3 CDKN2A TP53
21 anal carcinoma in situ 10.3 CDKN2A TP53
22 childhood embryonal testis carcinoma 10.3 EGFR TP53
23 oro-mandibular-limb hypogenesis syndrome 10.2 CDKN2A TP53
24 brain stem medulloblastoma 10.2 CDKN2A TP53
25 exudative glomerulonephritis 10.2 EGFR TP53
26 uterine disease 10.2 CDKN2A TP53
27 lymphangitis 10.2 KRT13 TP53
28 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A TP53
29 ovarian embryonal carcinoma 10.2 EGFR TP53
30 spastic ataxia 5 10.2 CDKN2A TP53
31 type 1 papillary adenoma of the kidney 10.2 TP53 UPK3A
32 gallbladder pleomorphic giant cell adenocarcinoma 10.2 CDKN2A TP53
33 chronic monocytic leukemia 10.2 CDKN2A EGFR TP53
34 allergic contact dermatitis 10.2 CDKN2A EGFR TP53
35 interstitial lung disease 10.2 CDKN2A EGFR TP53
36 breast epithelioid hemangioma 10.2 TP53 UPK3A
37 pyomyositis 10.2 CDKN2A EGFR TP53
38 connective tissue benign neoplasm 10.2 CDKN2A EGFR TP53
39 prostatic adenoma 10.2 CDKN2A EGFR TP53
40 marginal zone b-cell lymphoma 10.2 CDKN2A EGFR TP53
41 adult epithelioid sarcoma 10.2 CDKN2A TP53
42 paroxysmal nocturnal hemoglobinuria 10.2 CDKN2A EGFR TP53
43 occlusion precerebral artery 10.2 CDKN2A EGFR TP53
44 nasopharyngeal carcinoma 10.2 CDKN2A EGFR TP53
45 pearson syndrome 10.2 CDKN2A EGFR TP53
46 trachea squamous cell carcinoma 10.2 CDKN2A EGFR TP53
47 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.2 CDKN2A EGFR TP53
48 facial dermatosis 10.2 CDKN2A EGFR TP53
49 perivascular epithelioid cell tumor 10.2 KRT13 UPK3A
50 cervical verrucous carcinoma 10.2 CDKN2A TP53

Comorbidity relations with Vulva Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis Clitoris Cancer
Hypertension, Essential Localized Scleroderma
Vaginal Cancer Vulvar Dystrophy

Graphical network of the top 20 diseases related to Vulva Cancer:

Diseases related to Vulva Cancer

Symptoms & Phenotypes for Vulva Cancer

UMLS symptoms related to Vulva Cancer:

pruritus vulvae, pelvic pain

Drugs & Therapeutics for Vulva Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006

Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
3 Pharmaceutical Solutions Phase 4
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
Menthol Approved Phase 3 2216-51-5 16666
Amitriptyline Approved Phase 3 50-48-6 2160
Perphenazine Approved Phase 3 58-39-9 4748
Aluminum hydroxide Approved Phase 3 21645-51-2
Acetaminophen Approved Phase 3 103-90-2 1983
Petrolatum Approved Phase 3 8009-03-8
Dehydroepiandrosterone Approved, Nutraceutical Phase 3 53-43-0 9860744
16 interferons Phase 2, Phase 3, Phase 1
17 Coagulants Phase 3
18 Fibrin Tissue Adhesive Phase 3
19 Hemostatics Phase 3
20 Antineoplastic Agents, Hormonal Phase 3
21 Gastrointestinal Agents Phase 3
22 Adjuvants, Anesthesia Phase 3
23 Analgesics Phase 3,Phase 2
24 Analgesics, Opioid Phase 3
25 Anesthetics Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Central Nervous System Depressants Phase 3
29 Narcotics Phase 3
30 pancreatic polypeptide Phase 3,Phase 1
31 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
32 Anesthetics, Local Phase 3
33 Anti-Arrhythmia Agents Phase 3
34 Diuretics, Potassium Sparing Phase 3
35 Sodium Channel Blockers Phase 3
36 Adjuvants, Immunologic Phase 2, Phase 3, Phase 1
37 Interferon Inducers Phase 2, Phase 3
38 Analgesics, Non-Narcotic Phase 3,Phase 2
39 Dermatologic Agents Phase 3,Phase 2
40 Adrenergic Agents Phase 3
41 Amitriptyline, perphenazine drug combination Phase 3
42 Antidepressive Agents Phase 3
43 Antidepressive Agents, Tricyclic Phase 3
44 Antipsychotic Agents Phase 3
45 Neurotransmitter Agents Phase 3
46 Neurotransmitter Uptake Inhibitors Phase 3
47 Psychotropic Drugs Phase 3
48 Tranquilizing Agents Phase 3
49 Aluminum sulfate Phase 3
50 Antipyretics Phase 3

Interventional clinical trials:

(show top 50) (show all 166)
id Name Status NCT ID Phase
1 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
2 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
3 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Not yet recruiting NCT03051516 Phase 4
4 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Not yet recruiting NCT03180034 Phase 4
5 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
6 Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Completed NCT00003325 Phase 3
7 Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Completed NCT00898352 Phase 3
8 Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Completed NCT00028951 Phase 3
9 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Completed NCT00224744 Phase 3
10 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
11 Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence Completed NCT01148290 Phase 3
12 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
13 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
14 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
15 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3
16 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
18 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
19 Therapy to Prevent Sexual Pain in Breast Cancer Survivors Completed NCT01539317 Phase 3
20 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3
21 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3
22 Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia Recruiting NCT01861535 Phase 3
23 Physical Therapy as Adjuvant Treatment of Vulvodynia: a Randomized Controled Trial Recruiting NCT02871661 Phase 3
24 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Active, not recruiting NCT00943722 Phase 3
25 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3
26 Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine Active, not recruiting NCT01735006 Phase 3
27 A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls Active, not recruiting NCT02562508 Phase 3
28 Topical 5% Imiquimod Cream for Vulvar Paget's Disease Enrolling by invitation NCT02385188 Phase 3
29 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Not yet recruiting NCT03158220 Phase 3
30 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Not yet recruiting NCT02997553 Phase 3
31 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva Terminated NCT00006096 Phase 3
32 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
33 Imiquimod Treatment of CIN Lesions Terminated NCT02329171 Phase 3
34 Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Unknown status NCT00003525 Phase 2
35 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
36 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
37 Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Completed NCT00068406 Phase 2
38 Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva Completed NCT00014599 Phase 2
39 The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence Completed NCT01986725 Phase 2
40 Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar Completed NCT00476476 Phase 2
41 Effectiveness of an Individualized Symptom Education Program (ISEP) Completed NCT00275353 Phase 2
42 Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus Completed NCT00393263 Phase 2
43 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed NCT00545792 Phase 2
44 A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Completed NCT00551187 Phase 2
45 Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Completed NCT00520598 Phase 2
46 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2
47 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
48 Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment Completed NCT00941811 Phase 2
49 CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer Completed NCT00610740 Phase 2
50 Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus Completed NCT00757874 Phase 2

Search NIH Clinical Center for Vulva Cancer

Cochrane evidence based reviews: vulvar neoplasms

Genetic Tests for Vulva Cancer

Anatomical Context for Vulva Cancer

MalaCards organs/tissues related to Vulva Cancer:

Testes, Skin, Cervix

Publications for Vulva Cancer

Articles related to Vulva Cancer:

(show all 13)
id Title Authors Year
Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the "too difficult to do" box? ( 28034465 )
The Added Value of Pathology Review in Vulva Cancer: Results From a Population-based Cohort Study. ( 27513080 )
Could Sentinel Node Mapping of the Groin Cause Extranodal Metastasis in Vulva Cancer? ( 25412581 )
Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. ( 25225572 )
Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. ( 23725140 )
The comparative study of former and latest FIGO staging of vulva cancer. ( 22487921 )
Assessment of promising protein markers for vulva cancer. ( 19509584 )
An alternative approach to ganglion impar neurolysis under computed tomography guidance for recurrent vulva cancer. ( 17006101 )
Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. ( 16149671 )
Correspondence re: Weiderpass et al., Alcoholism and risk of cancer of cervix uteri, vagina, and vulva. Cancer Epidemiol. Biomark. Prev., 10: 899-901, 2001. ( 11895888 )
Inguinal node status by ultrasound in vulva cancer. ( 10739696 )
Cervical and vulva cancer: changes in FIGO definitions of staging. ( 8624311 )
T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. ( 7774837 )

Variations for Vulva Cancer

Cosmic variations for Vulva Cancer:

id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM498 HRAS skin,genital,carcinoma,NS c.182A>T p.Q61L 7
2 COSM12296 TP53 skin,lip,carcinoma,NS c.292C>T p.P98S 6
3 COSM10662 TP53 skin,lip,carcinoma,NS c.743G>A p.R248Q 6
4 COSM17598 PTCH1 skin,lip,carcinoma,NS c.550C>T p.Q184* 6
5 COSM26363 PTCH1 skin,lip,carcinoma,NS c.2446C>T p.Q816* 6

Expression for Vulva Cancer

Search GEO for disease gene expression data for Vulva Cancer.

Pathways for Vulva Cancer

GO Terms for Vulva Cancer

Cellular components related to Vulva Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.17 KRT13 PIP PLXDC2 SCN10A SERPINB3 SH3GL2

Biological processes related to Vulva Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 8.96 EGFR SH3GL2
2 replicative senescence GO:0090399 8.62 CDKN2A TP53

Sources for Vulva Cancer

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....